Implementation of Adaptive Unsharp Masking as a pre-filtering method for watermark detection and extraction

Digital watermarking has been one of the focal points of research interests in order to provide multimedia security in the last decade. Watermark data, belonging to the user, are embedded on an original work such as text, audio, image, and video and thus, product ownership can be proved. Various robust watermarking algorithms have been developed in order to extract/detect the watermark against such attacks. Although watermarking algorithms in the transform domain differ from others by different combinations of transform techniques, it is difficult to decide on an algorithm for a specific application. Therefore, instead of developing a new watermarking algorithm with different combinations of transform techniques, we propose a novel and effective watermark extraction and detection method by pre-filtering, namely Adaptive Unsharp Masking (AUM). In spite of the fact that Unsharp Masking (UM) based pre-filtering is used for watermark extraction/detection in the literature by causing the details of the watermarked image become more manifest, effectiveness of UM may decrease in some cases of attacks. In this study, AUM has been proposed for pre-filtering as a solution to the disadvantages of UM. Experimental results show that AUM performs better up to 11\% in objective quality metrics than that of the results when pre-filtering is not used. Moreover; AUM proposed for pre-filtering in the transform domain image watermarking is as effective as that of used in image enhancement and can be applied in an algorithm-independent way for pre-filtering in transform domain image watermarking

Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults

Copyright © 2013 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd.Background: Dysfunctional breathing/hyperventilation syndrome (DB/HVS) is a respiratory disorder, psychologically or physiologically based, involving breathing too deeply and/or too rapidly (hyperventilation) or erratic breathing interspersed with breath-holding or sighing (DB). DB/HVS can result in significant patient morbidity and an array of symptoms including breathlessness, chest tightness, dizziness, tremor and paraesthesia.DB/HVS has an estimated prevalence of 9.5%in the general adult population, however, there is little consensus regarding the most effective management of this patient group. Objectives: 1) To determine whether breathing exercises in patients with DB/HVS have beneficial effects as measured by quality of life indices. 2) To determine whether there are any adverse effects of breathing exercises in patients with DB/HVS Search methods: We identified trials for consideration using both electronic and manual search strategies. We searched CENTRAL, MEDLINE, EMBASE, and four other databases. The latest search was in February 2013. Selection criteria: We planned to include randomised, quasi-randomised or cluster randomised controlled trials (RCTs) in which breathing exercises, or a combined intervention including breathing exercises as a key component, were compared with either no treatment or another therapy that did not include breathing exercises in patients with DB/HVS. Observational studies, case studies and studies utilising a cross-over design were not eligible for inclusion. We considered any type of breathing exercise for inclusion in this review, such as breathing control, diaphragmatic breathing, yoga breathing, Buteyko breathing, biofeedback-guided breathingmodification, yawn/sigh suppression. Programs where exercises were either supervised or unsupervised were eligible as were relaxation techniques and acute-episode management, as long as it was clear that breathing exercises were a key component of the intervention. We excluded any intervention without breathing exercises or where breathing exercises were not key to the intervention

On the First Anthropic Argument in Astrobiology

We consider the little-known anthropic argument of Fontenelle dealing with the nature of cometary orbits, given a year before the publication of Newton's Principia. This is particularly interesting in view of the rapid development of the recently resurgent theories of cometary catastrophism and their role in the modern astrobiological debates, for instance in the "rare Earth" hypothesis of Ward and Brownlee.Comment: 16 pages, 2 figures, submitted to "Earth, Moon, and Planets

Women and non communicable diseases (chronic conditions)

Non-communicable diseases (cancer, cardiovascular disease, diabetes, chronic respiratory conditions, and musculo-skeletal conditions) are the number one cause of death and disablement for women and men globally and in Australia, with increasing recognition that women and men experience those conditions differently. This position paper examines the gender dimensions of those diseases to raise awareness, and to inform prevention and treatment guidelines. Building on the inequities for women documented in the AWHN Position Paper on Women’s Health and Wellbeing, this paper highlights the specific areas where gender blindness is occurring and the areas where change is needed. Despite the prevalence of Non-communicable diseases (NCDs) among women, there has been little emphases and even less action, on the differences that women experience in these diseases. Most guidelines and policies on NCDs are gender neutral. This has meant that women with non-communicable diseases have not received the level of support and services needed to ensure the best possible outcomes or that necessary research and education into gender differences has been funded. The lack of research into gender differences and the consequent lack of education for health providers and the population generally, potentially promotes poorer outcomes for women and increases gender inequities. When there is mounting evidence that women’s experience of NCDs is different to that of men’s experience, the gender neutrality of policies, research and education programs contributes to gender inequities. The impact of NCDs on women’s lives, the differences in risk factors for women than for men and the social determinants of NCDs are highlighted. Specific risks include, that: Lung cancer is responsible for more women’s deaths than breast cancer although more women are diagnosed with breast cancer than lung cancer Mortality rates from lung cancer in women are continuing to rise while they have plateaued or are dropping among men Chronic Obstructive Pulmonary Disease (COPD) occurs at lower levels of exposure to tobacco smoking in women than men women with diabetes have a higher risk of stroke than their male counterparts women with diabetes have poorer survival after stroke than men. This paper also highlights the low rate of women in research trials and the low levels of reporting of sex-disaggregated findings. These indicate that treatment recommendations are more generalisable for males than females and the research benefits are therefore greater for men. In turn, this accords a lower status in research to women’s health. Failure to act on gender differences in non-communicable disease costs lives. It is no longer satisfactory for prevention and treatment guidelines to remain gender neutral. Leadership from governments and peak health bodies is required to drive change in both policy and research. Understanding the ways in which gender interacts with NCDs will be enhanced by explicitly mainstreaming gender in policy, research, treatment guidelines and professional and public education. This paper recommends actions that can be taken to redress these problems, and achieve gender aware, gender sensitive and gender transformative care for women. &nbsp

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events

An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol.Search methodsWe identified trials using the Cochrane Airways Group Specialised Register of trials. We checked manufacturers' websites of clinical trial registers for unpublished trial data and also checked Food and Drug Administration (FDA) submissions in relation to formoterol and salmeterol. The date of the most recent search was January 2012.Selection criteriaWe included controlled, parallel-design clinical trials on patients of any age and with any severity of asthma if they randomised patients to treatment with regular formoterol versus regular salmeterol (without randomised inhaled corticosteroids), and were of at least 12 weeks' duration.Data collection and analysisTwo authors independently selected trials for inclusion in the review and extracted outcome data. We sought unpublished data on mortality and serious adverse events from the sponsors and authors.Main resultsThe review included four studies (involving 1116 adults and 156 children). All studies were open label and recruited patients who were already taking inhaled corticosteroids for their asthma, and all studies contributed data on serious adverse events. All studies compared formoterol 12 mu g versus salmeterol 50 mu g twice daily. The adult studies were all comparing Foradil Aerolizer with Serevent Diskus, and the children's study compared Oxis Turbohaler to Serevent Accuhaler. There was only one death in an adult (which was unrelated to asthma) and none in children, and there were no significant differences in non-fatal serious adverse events comparing formoterol to salmeterol in adults (Peto odds ratio (OR) 0.77; 95% confidence interval (CI) 0.46 to 1.28), or children (Peto OR 0.95; 95% CI 0.06 to 15.33). Over a six-month period, in studies involving adults that contributed to this analysis, the percentages with serious adverse events were 5.1% for formoterol and 6.4% for salmeterol; and over a three-month period the percentages of children with serious adverse events were 1.3% for formoterol and 1.3% for salmeterol.Authors' conclusionsWe identified four studies comparing regular formoterol to regular salmeterol (without randomised inhaled corticosteroids, but all participants were on regular background inhaled corticosteroids). The events were infrequent and consequently too few patients have been studied to allow any firm conclusions to be drawn about the relative safety of formoterol and salmeterol. Asthma-related serious adverse events were rare and there were no reported asthma-related deaths

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

BackgroundETC-1002 is an oral, once-daily, first-in-class medication being developed to treat hypercholesterolemia.ObjectivesTo compare 2 doses of ETC-1002, alone or combined with ezetimibe 10 mg (EZE), vs EZE monotherapy for lowering low-density lipoprotein cholesterol (LDL-C).MethodsThis phase 2b, multicenter, double-blind trial-evaluated hypercholesterolemic patients (LDL-C, 130 to 220 mg/dL) with (n = 177) or without (n = 171) muscle-related intolerance to ≥2 statins; 1 at lowest approved dose. Subjects were randomized to 12-week treatment with ETC-1002 120 mg or ETC-1002 180 mg alone, EZE alone, ETC-1002 120 mg plus EZE, or ETC-1002 180 mg plus EZE.ResultsEZE alone lowered LDL-C by 21%, whereas ETC-1002 monotherapy with 120 mg or 180 mg reduced LDL-C by 27% (P = .0008 vs EZE) and 30% (P < .0001 vs EZE), respectively. The combination of ETC-1002, 120 mg or 180 mg plus EZE reduced LDL-C by 43% and 48%, respectively (both P < .0001 vs EZE). ETC-1002 alone or combined with EZE also reduced non–high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, LDL particle number, and high-sensitivity C-reactive protein compared with EZE alone. Across all treatment groups, statin-intolerant patients reported more muscle-related adverse events than did statin-tolerant patients. ETC-1002 was safe and well tolerated, and rates of muscle-related adverse events were similar in all treatment groups.ConclusionsIn patients with and without statin intolerance, daily treatment with ETC-1002 120 mg and 180 mg alone or with EZE reduced LDL-C more than EZE alone and had a similar tolerability profile (NCT01941836)

Conservative management of low back pain

Back pain is prevalent worldwide, but back pain disability has reached epidemic proportions in many industrialised societies. Few patients have serious medical pathology or direct neurological involvement requiring surgery. Although the causes remain unclear, physical stress and its consequences on discs, facet joints and supporting soft tissues at work or leisure are important, sometimes aggravated by adverse psychosocial factors. Modern management emphasises the role of self-care, beginning in primary care with the first episode. Without root compression, bed rest should not exceed 48 hours. Emphasis is on encouraging a rapid return to physical fitness and other activities, including employment, acknowledging that returning to a normal life may require working through pain. Medication facilitates this. No one should remain in pain beyond six weeks without being referred to a specialist service for a physical and psychosocial assessment by appropriately trained professionals and with consultant support for investigation, pain management and rehabilitation when needed